middle.news
BioMarin’s $4.8B Buyout of Amicus Secures Dimerix’s US Licensing Future
9:25am on Monday 22nd of December, 2025 AEDT
•
Healthcare
Read Story
BioMarin’s $4.8B Buyout of Amicus Secures Dimerix’s US Licensing Future
9:25am on Monday 22nd of December, 2025 AEDT
Key Points
BioMarin to acquire Amicus Therapeutics for US$4.8 billion
Dimerix’s US licensing agreement with Amicus included in acquisition
Dimerix eligible for up to US$590 million in milestone payments plus royalties
International licensing deals remain unaffected
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Dimerix (ASX:DXB)
OPEN ARTICLE